primary defect is not very strong. The best documented biochemical abnormality that might be playing a 'primary' role is the increase in the number of D2 receptors observed in post mortem and in in vivo studies (Owen et al., 1978; Seeman et al., 1984; Wong et al., 1986a) . Recent in vivo studies suggcst that this abnormality is not seen in untreated schizophrenic patients (Farde et al., 1987) .
Evidence that blockade of dopaminergic receptors by neuroleptic drugs contributes to their therapeutic action is stronger (Crow, 1987) .
Other neurotransmitter systems that have been extensively discussed include other monoamines (noradrenaline, serotonin, acetylcholine) and GABA.
Understanding of excitatory transmission mediated by dicarboxylic amino acids and related compounds has dramatically advanced in the last few years. It has become evident that a primary abnormality in these excitatory systems could explain the clinical phenomena of schizophrenia, including the data relating to dopaminergic transmission.
Therapeutic approaches based on modification of such transmission require urgent investigation.
Endogenous neurotransmitters and the 'glutamate' receptor A neurotransmitter role at fast excitatory recep-tors appears probable for glutamate, aspartate and their sulphonic and sulphinic analogous (such as homocysteate). Several dipeptide and tripeptide derivatives of glutamate and aspartate are found in the brain. Their functional role is not yet clear.
Receptors at which glutamate acts have been classified according to their preferred (exogenous) agonists (in the same way as acetylcholine receptors are classified as 'nicotinic' and 'muscarinic'). Thus three major categories of post-synaptic glutamate receptor have been defined, the N-methyl-D-aspartate (NMDA)receptor, the kainate receptor and the quisqualate receptor (Davies et al., 1982) . It is thought that the NMDA receptor may exist in two forms (Stone and Burton, 1988). There is probably a further receptor at which glutamate acts. Evidence about a presynaptic receptor at which glutamate and 2-amino-4-phosphonobutyrate act is controversial, an uptake or exchange site may be involved. The three major receptor subtypes (such as NMDA, kainate and quisqualate) have distinctive regional distributions in the brain as revealed by receptor autoradiography (Monaghan et al., 1983) . Kainate receptors have their highest density in the mossy fibre system in the hippocampus, but are also prominent in superficial and deep laminae of the neocortex (Patel, Meldrum and Collins, 1986) . NMDA receptors are prominent in the dendritic laminae of the hippocampus and in the cortex. Quisqualate receptors are also prominent in hippocampus, cortex and cerebellum (Monaghan, Yao and Cotman 1984) .
Activation of these receptors causes depolarization of the neuronal membrane through the opening of cationic channels. Activ ation of kainate or quisqualate receptor subtypes permits the entry of Na+. Activation of NMDA receptors permits the entry of Na+ and Ca2+. However the channel opened by NMDA is blocked in a voltage-dependent manner by Mg'+, when Mg2 17is present in the concentration normally found in the extracellular fluid. Depolarization induced by the activation of kainate or quisqualate receptors overcomes this block. The NMDA receptor has an allosteric site at which glycine acts to increase the frequency of channel opening induced by NMDA (Johnson and Ascher, 1987) . There is also a site at which phencyclidine, and other dissociative anaesthetics such as ketamine, and sigma opiates such as cyclazocine and N-allylnormetazocine and also dextrorphan, act to block the conductance change produced by NMDA. This may relate to the psychotomimetic action of phencyclidine and is discussed in more detail below.
Abnormalities in glutamate and glutamate receptors in schizophrenia Studies that have been performed relate to three main areas -plasma amino acid concentrations, cerebrospinal fluid amino acid concentrations and receptor binding studies in postmortem brain tissue. Plasma glutamate and aspartate levels do not appear to be abnormal in schizophrenic patients (Kim et al., 1980; Bjerkenstedt et al., 1985) . However the glutamate concentration in cerebrospinal fluid from schizophrenic patients was found by Kim et al. (1980) to be halt that in normal controls (13.4 nmol/ml n = 20, versus 25.8 nmol/ml n = 44). In postmortem brain tissue a 25-50 per cent increase in the binding of [3H]kainic acid was found in the medial frontal and eye-movement cortical areas of schizophrenic patients (Nishikawa, Takashima and Toro, 1983) . Such an abnormality could arise through upregulation of receptors following decreased neurotransmitter release. The cortical location of the abnormality could contribute to the frontal deficits and the abnormality of eye tracking observed in schizophrenic patients. In a very recent study Kerwin et al. (1988) have shown a decrease in kainate binding in the left hippocampus of schizophrenic brains (compared with age-matched controls). It seems unlikely that this change is merely secondary to the cellular pathology found in the schizophrenic brain (Falkai and Bogerts, 1986) as the pathology occurs bilaterally. It is consistent with the substantial body of psychophysiological evidence for left-sided abnormality in temporal lobe function in schizophrenia (Newlin, Carpenter and Golden, 1981) and with other physiological evidence for left hemisphere dysfunction such as increased blood flow in the left globus pallidus (Early et al., 1987) .
Interactions between glutamatergic and dopaminergic transmission
Interactions of three kinds have been described.
The release of dopamine is subject to glutamatergic control. The release of glutamate is influenced by dopamine and neuroleptics. The postsynaptic action of glutamate is enhanced by dopamine.
The control of dopamine release by glutamatergic mechanisms has been observed in studies performed in vitro and in vivo. , 1985) . It now seems likely that there are two sites, the PCP/ sigma and the sigma site, with many ligands in common but differentiated by the preferential binding of N-allylnormetazocine to the sigma site. Haloperidol displaces PCP from the sigma site.
Electrophysiological studies in the rat spinal cord have shown that phencyclidine, the sigma opioids and the dissociative anaesthetic ketamine, all antagonize the excitatory effect of NMDA (Anis et al., 1983; Berry, Dawkins and Lodge, 1984) . This effect is produced via the PCP/sigma site, not the sigma site. The anticonvulsant, MK 801, also potently displaces PCP but is only very weakly active at the sigma site. It is also a non-competitive antagonist of the excitatory action of NMDA (Wong et al., 1986b) . Binding of PCP or of MK 801 is enhanced in the presence of glutamate or aspartate, and blockade of NMDA-induced excitation is accelerated by activation of the receptor. These and other observations have lead to the suggestion that PCP and MK 801 act on the open channel.
Factors that compete with PCP for binding to rat brain membranes have been isolated from porcine brain. One that appears to be a peptide of approximate molecular weight 3000 daltons competes with PCP for its binding site and has been called 'a-endopsychosin' (Quirion et al., 1984) . Another, called '~3-endopsychosin', inhibits N-allylnormetazocine (SKF 10047) receptor preferentially to PCP binding suggesting that it interacts with the sigma site (Contreras, DiMaggio and O'Donohue, 1987) . These compounds need to be further characterized in terms of their chemistry and biological activity. The present data are by no means conclusive but have led to the suggestion that there are endogenous psychotomimetic peptides in the brain that act by blocking NMDA-mediated excitation.
It is also currently proposed that the psychotomimetic action of PCP and the sigma opioids is due to blockade of excitation at the NMDA receptor. This hypothesis is by no means proven; the psychotomimetic action could be related to action at the sigma receptor or at other less well-defined sites. PCP and ketamine act on many neurotransmitter systems including the monoamines. They also potently block a presynaptic potassium conductance (Bartschat and Blaustein, 1986; Sorensen and Blaustein, 1988) . The hypothesis appears, however, to be supported by behavioural observations in rats and pigeons indicating that direct NMDA antagonists such as 2-amino-5-phosphono-valerate (which lack effects on the sigma receptor, presynaptic potassium conductance, or monoaminergic neurotransmission) produce similar motor disturbances (catalepsy, stereotypies) to PCP (Koek, Woods and Ornstein, 1987; Koek et al., 1986) .
A maturational defect in the NMDA receptor?
The NMDA receptor undoubtedly plays a crucial role in synaptic plasticity determining patterns of connectivity in development and controlling long-term changes in synaptic function in adults. Thus it is crucially involved in the establishment °o f binocular connectivity in the kitten cortex (Kleinschmidt, Bear and Singer, 1987) and of the occurrence of long-term potentiation in the hippocampus following brief tetanic stimulation (Morris et al., 1986). These findings and the data relating to the psychotomimetic effect of non-competitive NMDA antagonists have lead Etienne and Baudry (1987) to propose another possible relationship between schizophrenia and the NMDA receptor system. They suggest that one of the genes that predisposes to schizophrenia is linked to the functioning or maturation of the NMDA receptor/ion channel complex. There are marked developmental changes in the second messenger (phosphatidylinositol) responses to NMDA. It is proposed that the genetic abnormality in schizophrenic patients (and perhaps in their relatives) gives rise to a delay or failure in the transition from the juvenile to adult form of the NMDA receptor system. The major synaptic reorganization occurring during adolescence (which is manifest as a loss of synaptic density; Huttenlocher, 1979) is disrupted and this perhaps with sustained abnormal functioning of the NMDA receptor system contributes to the development of schizophrenia, or enhanced creativity. It could also explain why a genetically determined illness does not manifest itself until adolescence. There are of course numerous other mechanisms which could account for this delayed onset (Weinberger, 1987) .
Conclusions
A primary or secondary abnormality of excitatory amino acid neurotransmission could be a causal mechanism responsible for the clinical manifestations of schizophrenia. This proposal is supported by evidence of various kinds, including evidence for psychotomimetic actions tentatively related to the NMDA receptor, abnormalities in the density of kainate receptors and interactions between excitatory amino acids and dopamine that could explain the dopamine-related phenomena in acute psychosis in terms of augmented glutamatergic function (involving either NMDA or quisqualate receptors). The appropriate therapeutic strategy will be very different according to the importance of NMDA or non-NMDA receptors. In this respect recent progress in the development of specific kainate and quisqualate antagonists (Frey et al., 1988; Honore et al., 1987) offers the prospect of drugs that could be tested in appropriate animal models and perhaps in man. 
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